CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply

Fennell, D.A., Griffiths, G., Ottensmeier, C. et al. (4 more authors) (2022) CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? – Authors' reply. The Lancet Oncology, 23 (1). e14-e15. ISSN 1470-2045

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2021 Elsevier Ltd. This is an author produced version of a paper subsequently published in The Lancet Oncology. Uploaded in accordance with the publisher's self-archiving policy. Article available under the terms of the CC-BY-NC-ND licence (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Dates:
  • Published (online): 29 December 2021
  • Published: January 2022
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 14 Jan 2022 14:33
Last Modified: 29 Jun 2022 00:13
Status: Published
Publisher: Elsevier
Refereed: Yes
Identification Number: 10.1016/S1470-2045(21)00722-1
Related URLs:
Open Archives Initiative ID (OAI ID):

Export

Statistics


CORE (COnnecting REpositories)